Bernzott Capital Advisors trimmed its stake in shares of Encompass Health Co. (NYSE:EHC - Free Report) by 23.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 64,940 shares of the company's stock after selling 19,359 shares during the period. Encompass Health comprises about 3.0% of Bernzott Capital Advisors' holdings, making the stock its 20th biggest holding. Bernzott Capital Advisors owned 0.06% of Encompass Health worth $5,997,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also modified their holdings of the stock. West Coast Financial LLC grew its holdings in shares of Encompass Health by 1.9% during the 4th quarter. West Coast Financial LLC now owns 48,588 shares of the company's stock valued at $4,487,000 after acquiring an additional 917 shares in the last quarter. USA Financial Formulas boosted its holdings in Encompass Health by 7.1% in the fourth quarter. USA Financial Formulas now owns 3,642 shares of the company's stock worth $336,000 after purchasing an additional 240 shares in the last quarter. Park Avenue Securities LLC increased its position in Encompass Health by 44.7% during the fourth quarter. Park Avenue Securities LLC now owns 6,737 shares of the company's stock worth $622,000 after buying an additional 2,082 shares during the last quarter. Oak Thistle LLC bought a new position in Encompass Health during the fourth quarter valued at about $2,099,000. Finally, Pallas Capital Advisors LLC bought a new stake in shares of Encompass Health during the 4th quarter worth about $237,000. Institutional investors and hedge funds own 97.25% of the company's stock.
Encompass Health Trading Up 0.3 %
Shares of EHC traded up $0.27 during trading hours on Friday, reaching $94.68. The stock had a trading volume of 471,076 shares, compared to its average volume of 550,343. The company has a market cap of $9.54 billion, a P/E ratio of 22.87, a P/E/G ratio of 1.09 and a beta of 0.89. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. The firm has a 50-day moving average of $97.56 and a 200 day moving average of $93.88. Encompass Health Co. has a 52 week low of $69.76 and a 52 week high of $104.55.
Encompass Health (NYSE:EHC - Get Free Report) last released its quarterly earnings results on Monday, October 28th. The company reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.09. The firm had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.33 billion. Encompass Health had a return on equity of 17.60% and a net margin of 8.10%. The company's revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter last year, the business posted $0.86 EPS. On average, sell-side analysts expect that Encompass Health Co. will post 4.29 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of research analysts recently weighed in on the company. KeyCorp raised their price objective on Encompass Health from $115.00 to $117.00 and gave the company an "overweight" rating in a research note on Tuesday, October 29th. Truist Financial reissued a "buy" rating and issued a $116.00 price target (up previously from $108.00) on shares of Encompass Health in a research report on Wednesday, October 30th. Barclays upped their price objective on shares of Encompass Health from $109.00 to $116.00 and gave the stock an "overweight" rating in a report on Tuesday, October 29th. UBS Group lifted their target price on shares of Encompass Health from $100.00 to $110.00 and gave the stock a "buy" rating in a report on Wednesday, September 25th. Finally, Royal Bank of Canada upped their price target on shares of Encompass Health from $105.00 to $110.00 and gave the company an "outperform" rating in a report on Wednesday, October 30th. Nine research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Encompass Health currently has an average rating of "Buy" and a consensus price target of $107.11.
Read Our Latest Analysis on EHC
About Encompass Health
(
Free Report)
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.
Further Reading
Before you consider Encompass Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Encompass Health wasn't on the list.
While Encompass Health currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
